Baker, T.S., Bose, C.C., Caskey-Finney, H.M., King, D.J., Lawson, A.D.G.,
Lyons, A., Mountain, A., Owens, R.J., Rolfe, M.R., Sehdev, M., Yarranton, G.T.
and Adair, J.R.
"Humanization of an anti-mucin antibody for breast and ovarian cancer therapy"
In "Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment" (1994) Ed. Ceriani, R.L., Plenum Press, New York pp61-82.
Banfield, M.J., King, D.J., Mountain, A. and Brady, R.L. "VL:VH Domain rotations in engineered antibodies: Crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs" Proteins (1997) 29:161-171.
|Acceptor Antibody:||Human IgG4P | k (IgG4P differs at S241P to allow complete disulphide bridge formation at the hinge)|
|Antigen:||Polymorphic Epithelial Mucin (PEM) in Human Milk Fat globule (HMFG)|
|Design:||CDR-grafting plus consensus residues at atypical positions in the human FRs.|
|Frameworks:||VH EU | VL EU|
|CDRs:||All 6 VH and VL, Kabat Definition.|
|Binding:||"Similar" to mouse mAb as measured by competition binding assays. Second paper states it has "increased affinity (relative potency of 213%)".|
|Expression:||transient CHO L761h and stable NS0 cells|
|Comment:||Murine sequence not yet available.|
|Clinical Indication:||Breast and ovarian cancers.|
|José Saldanha © 1997-8. Birkbeck College, London WC1E 7HX.|